Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 16, 2024

BUY
$31.31 - $44.19 $158,459 - $223,645
5,061 Added 74.66%
11,840 $498,000
Q3 2023

Oct 12, 2023

BUY
$18.55 - $39.96 $125,750 - $270,888
6,779 New
6,779 $260,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Legato Capital Management LLC Portfolio

Follow Legato Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legato Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Legato Capital Management LLC with notifications on news.